Pharmacophore modeling of cytochromes P450

被引:99
作者
de Groot, MJ [1 ]
Ekins, S
机构
[1] Pfizer Global Res & Dev, Dept Mol Informat Struct & Des, Sandwich Labs, Sandwich CT13 9NJ, Kent, England
[2] Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
关键词
cytochrome P450; drug-drug interactions; pharmacophore models; 3D-QSAR; catalyst;
D O I
10.1016/S0169-409X(02)00009-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Understanding the binding of ligands in the active site of a membrane-bound protein is difficult in the absence of a crystal structure. When these proteins are the enzymes involved in drug metabolism, it leaves little option but to use site-directed mutagenesis and in vitro studies to provide critical information relating to determinants of binding affinity. Pharmacophore models and three-dimensional quantitative structure-activity relationships have been used either alone or in combination with protein homology models to provide this information for cytochrome P450s. At present, their application has been directed to the major enzymes but this may escalate in future as more in vitro data are generated for other P450s. The following review outlines the methodologies and models as well as future prospects for applying these technologies to P450s in the hope that future drugs will be selected with increased metabolic stability and fewer incidences of undesirable drug-drug interactions. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:367 / 383
页数:17
相关论文
共 104 条
[82]   Comparative molecular field analysis of non-steroidal aromatase inhibitors: An extended model for two different structural classes [J].
Recanatini, M ;
Cavalli, A .
BIOORGANIC & MEDICINAL CHEMISTRY, 1998, 6 (04) :377-388
[83]   Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function [J].
Ridderström, M ;
Masimirembwa, C ;
Trump-Kallmeyer, S ;
Ahlefelt, M ;
Otter, C ;
Anderson, TB .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 270 (03) :983-987
[84]   THEORETICAL-STUDY ON THE METABOLISM OF CAFFEINE BY CYTOCHROME-P-450 1A2 AND ITS INHIBITION [J].
SANZ, F ;
LOPEZDEBRINAS, E ;
RODRIGUEZ, J ;
MANAUT, F .
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS, 1994, 13 (03) :281-284
[85]   Properties of cytochrome P450 isoenzymes and their substrates .1. active site characteristics [J].
Smith, DA ;
Ackland, MJ ;
Jones, BC .
DRUG DISCOVERY TODAY, 1997, 2 (10) :406-414
[86]   Properties of cytochrome P450 isoenzymes and their substrates .2. properties of cytochrome P450 substrates [J].
Smith, DA ;
Ackland, MJ ;
Jones, BC .
DRUG DISCOVERY TODAY, 1997, 2 (11) :479-486
[87]   SPECULATIONS ON THE SUBSTRATE STRUCTURE ACTIVITY RELATIONSHIP (SSAR) OF CYTOCHROME-P450 ENZYMES [J].
SMITH, DA ;
JONES, BC .
BIOCHEMICAL PHARMACOLOGY, 1992, 44 (11) :2089-2098
[88]   Conformational modulation of human cytochrome P450 2E1 by ethanol and other substrates: A CO flash photolysis study [J].
Smith, SV ;
Koley, AP ;
Dai, RK ;
Robinson, RC ;
Leong, H ;
Markowitz, A ;
Friedman, FK .
BIOCHEMISTRY, 2000, 39 (19) :5731-5737
[89]   New aromatase inhibitors.: Synthesis and biological activity of aryl-substituted pyrrolizine and indolizine derivatives [J].
Sonnet, P ;
Dallemagne, P ;
Guillon, J ;
Enguehard, C ;
Stiebing, S ;
Tanguy, J ;
Bureau, R ;
Rault, S ;
Auvray, P ;
Moslemi, S ;
Sourdaine, P ;
Séralini, GE .
BIOORGANIC & MEDICINAL CHEMISTRY, 2000, 8 (05) :945-955
[90]   DEVELOPMENT OF A PHARMACOPHORE FOR INHIBITION OF HUMAN LIVER CYTOCHROME-P-450 2D6 - MOLECULAR MODELING AND INHIBITION STUDIES [J].
STROBL, GR ;
VONKRUEDENER, S ;
STOCKIGT, J ;
GUENGERICH, FP ;
WOLFF, T .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (09) :1136-1145